Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(5 sites)

United States

Mayo Clinic Cancer Center, Jacksonville, Florida

University of Kansas Cancer Center, Fairway, Kansas

Belgium

Uz Leuven, Leuven

Chu Liege, Liège

AZ DELTA, Roeselare